Evofem Biosciences to Participate in Investor Conferences
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.
Details
News Market Reaction – EVFM
The recorded move for EVFM in the trading session of this news was -1.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows:
H.C. Wainwright 23rd Annual Global Investment Conference | |
Format: | Corporate presentation |
Date: | Monday, September 13, 2021 |
Time: | 7:00 a.m. ET (4:00 a.m. PT) |
Morgan Stanley Virtual Global Healthcare Conference | |
Format: | Fireside chat |
Date: | Tuesday, September 14, 2021 |
Time: | 12:30 – 1:00 p.m. ET (9:30 -10:00 a.m. PT) |
Webcasts of both events will be available through the Events section of the Evofem website at https://evofem.investorroom.com/events for 30 days.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-investor-conferences-301367047.html
SOURCE Evofem Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.